CN102533978A - Kit and method for detecting horizontal in situ hybridization of MICRORNA-373 at the early pathological evolution stage of a variety of cancers and application thereof - Google Patents
Kit and method for detecting horizontal in situ hybridization of MICRORNA-373 at the early pathological evolution stage of a variety of cancers and application thereof Download PDFInfo
- Publication number
- CN102533978A CN102533978A CN2011104196205A CN201110419620A CN102533978A CN 102533978 A CN102533978 A CN 102533978A CN 2011104196205 A CN2011104196205 A CN 2011104196205A CN 201110419620 A CN201110419620 A CN 201110419620A CN 102533978 A CN102533978 A CN 102533978A
- Authority
- CN
- China
- Prior art keywords
- hybridization
- cancer
- microrna
- kit
- test kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention discloses a kit for detecting in situ hybridization, comprising a hybridization probe and a marker. The invention further discloses a method for detecting the in situ hybridization of MICRORNA-373 which is closely related to the early pathological evolution of a variety of cancers by using the kit. The method comprises the following steps: (1) making RNA to be detected in a substrate contact the hybridization probe to form a hybrid complex under the condition that the hybridization probe can form the stable hybrid complex together with a target sequence; and (2) detecting the hybrid complex. The kit and the method can be used for detecting the expression quantity of the MICRORNA-372 and the MICRORNA-373 on the RNA level earlier than the existing medical imaging technique and the existing clinical biochemical detection indicator and can realize the real screening of the RNA level at the earlier stage of canceration. The method is simple and convenient to operate, has low cost and can be popularized and applied to the county and district level hospitals.
Description
Technical field
The present invention relates to field of biological detection, more particularly, relate to develop the correlation detection technology that rna expression changes (pathology evolution process) with various cancer pathology.
Background technology
According to the data that domestic and international authoritative institution provides, the newly-increased number 2,600,000 of the annual cancer of China, death toll nearly 2,100,000; The patient more than 700 ten thousand; The annual newly-increased cancer patients 8,000,000 in the whole world, death toll is near 8,000,000, and the patient has more than 8,400 ten thousand people approximately; To double to the above number of the year two thousand twenty, this is one group of fearful numeral.Cancer diagnosis and treatment cost is increasingly high; (poor area maybe be higher by cancer patients's year medical expense 200,000; Developed regions possibly exceed 200,000 far away), more than 700 ten thousand patients, annual cost is 1.4 trillion Renminbi; Deduction cost 35% is about 400,000,000,000, has every year 1000000000000 Renminbi to consume in vain approximately.And the cancer patients is most of can be dead soon after treatment.Therefore, existing clinical cancer diagnosis and treatment pattern must change, and innovative point of the present invention is to accomplish preventative examination in advance, in time gets involved preventative regulation and control and prophylactic treatment then, accomplishes preventiveing treatment of disease of gene level cancer.
An annual report has been done by eight tame units such as U.S. sanitary research institute in 2005, cancer research institute, Disease Control and Prevention Center; Anticancer Great War to initiation in 1972 is looked back; Report thinks that the mankind are failures in anticancer Great War; Conclusion is that cancer mortality does not reduce, and it is enumerated out and causes the Several Factors of anticancer Great War failure to be: 1. tumour cell heterogeneous (polymorphum); 2. tumor cell drug resistance; 3. cancer therapy drug mentality of designing imperfection (animal model designs not science) etc.Simultaneously, also propose to examine closely again the measure of existing diagnosis and treatment cancer in this report.
The inventor is in the middle discovery that studies for a long period of time, and the major reason that causes cancer mortality not fallen is to accomplish real early diagnosis.Come diagnosing cancer according to existing clinical medicine image (B ultrasonic, CT, zeugmatography etc.) and with other biochemistry (cancer antigen, CEACAMS, carbohydrate hormone, the cytolemma factor, the nucleus factor, cell streaming technology) index; All be that tumour forms the back diagnosis; The former will learn in a organized way and change or existing occupying lesion, latter's major part be tumour form the back secreted, discharge or the affinity tag of tumour.The clinical idea of tradition thinks that occupancy cancer piece is the diagnosis that belongs to early-stage cancer under 2 centimeters; This notion is worth conscientiously discussing, and it is rigorous inadequately that 2 centimeters early stage these of following cancer piece genus define science, analyzes from the cytology angle; 1 centimeter lump has 100,000,000 tumour cells approximately; Its three-dimensional cell stack number of 2 centimeters lump is far above 200,000,000 tumour cells, produces from canceration early stage to the mono-clonal cancer cells and forms 2 centimeters cancer piece, and its pathology evolution process is quite long; Possibly be (except the special case) more than 5 years or 10 years or even 10 years; What be difficult to confirm is in this pathology evolution process, and lump is unique spot of cancer and independent focus, and possible cancer cells is moved to other tissue or organ growth already.Clinical study confirms already, in case when forming lump, other cancer cells is moved to other position clonal growth through different approaches, in case behind the excision primary tumor, other organ recurrent foci or multiple cancer piece kitchen range successively form.Therefore; Whether define in early days with the cancerous swelling piece size below 2 centimeters clinically, rigorous inadequately (some case is when finding primary lesion; Find metastatic lesion simultaneously; Not in the content of our statement), at this moment be diagnosis in late period and treatment of late stage in fact, this is the true cause that causes cancer mortality not fallen.
Along with molecular biotechnology is perfect day by day, functional genomics, the deep expansion of research such as cancer genomics in order to seek more early stage diagnosing cancer, treatment cancer and preventing cancer, makes great progress.So far, we might do more accurate early screening and diagnosis on the one-level functional transcription product (mRNA level or microRNA) of gene, preceding in canceration early stage or cancer cells formation (mono-clonal), just can accomplish early prediction and examination.The present invention adopts the nucleic acid hybridization in situ technology, selects many group clinical samples (cancer patient, high risk population, normal control), and check and analysis are carried out in the early warning of MICRORNA-373 gene and various cancers.
MiRNA (microRNA/miRNA) is the few ribonucleic molecule that a segment length is about 22 nucleotides, and they can suppress translation or cause the degraded of mRNA to reduce the performance of gene by regulation and control mRNA.Many discovering arranged recently, and miRNA and cancer have the dependency of height.Therefore inference miRNA possibly be of cancerization process lead because of.Up to the present; On human body, there are 700 miRNA of surpassing to come to light; And nearly about 100 miRNA is identified with human cancer and has dependency; This wherein includes kinds of tumors such as esophagus cancer, breast cancer, leukemia, lung cancer, the cancer of the brain, liver cancer, carcinoma of the colon and rectum, glioma, pituitary tumor in esophageal cancer cell; We find that the performance of cancer suppressor protein-LATS2 receives that miR-373 suppresses and in esophageal cancer cell strain and esophagus cancer clinical tissue, the performance of LATS2 and miR-373 has opposite tendency.We also find in esophageal cancer cell, to suppress or excessively show miR-373, and the growth of cell can be affected.Comprehensive The above results, we find that miR-330 and miR-373 all can see through the growth that its target proteins of regulation and control influences esophageal cancer cell.In addition, this research also provides the new direction of treating esophagus cancer in the future clinically.
Though this a kind of endogenic microRNA s constantly has new member to come to light at present; But have only miRNAs function seldom to be determined; The people such as P. Mathijs Voorhoeve of Holland cancer research institute for the formation function of further confirming miRNAs the most of miRNAs carrier cloning of a mankind expression library, obtained corresponding D NA barcode arrays.Again through with the screening of the relevant miRNA of cellular oncogene; The researchist has recognized two miRNAs---miR-372 and miR-373, and these two miRNAs are positioned at the initial cell canceration of oncogene RAS and active wild type p53 and the key factor of tumourization.And the researchist finds that also these miRNAs have also suppressed the effect of the CDK supressor of p53 mediation, and this effect possibly be the expression through direct prevention TIF LATS2.These have proved that all miRNAs is a kind of new a kind of oncogene that can promote the generation of human reproduction's cell tumour through inhibition p53 approach.The inventor finds that under study for action microRNA-373 has the obvious expression quantitative changeization various cancer patientss (particularly esophagus cancer), cancer high risk population, normal control people, and microRNA-373 is become as the various cancers of early screening has very important clinical diagnosis meaning early stage.MICRORNA-373 becomes high expression level in early stage (particularly esophagus cancer) and the canceration process in various cancers.He do in examination in canceration early stage, and various cancer therapy after recurrence, shift early warning very important clinical meaning also arranged.
The contriver is in long term studies; Drawn a kind of new concept, the clinical diagnosis and treatment pattern of cancer and other clinical major disease must change, and can not only stop present treating the disease affected (morbidity back diagnosis and treatment); Accomplish preventative diagnosis and treatment; Accomplish treating the disease affected, only in this way could reduce the M & M of major disease, reduce social cost and medical treatment cost.Therefore, the contriver innovates theoretical and technical in the rna level kit for screening and medicine of exploitation and production major disease.Particularly screen clinical samples (normal population, cancer high risk population, tumour patient); Broken through healthy tissues and tumor tissues consistency research and development thinking relatively, sought and developed the rna level that becomes before the cancer, developed closely related with cancer early gene physiopathology; And the extremely important target of clinical meaning; Tumour is clinically formed the preventative diagnosis and treatment that diagnosis and treatment pattern in back becomes tumour, striven for the time and the space of tumor diagnosis and treatment, reach preventing cancer.
At present all adopt the common technology of present research microRNA express spectra to mainly contain high flux gene chip analytical technologies such as Northern hybridization, expression chip, real-time fluorescence quantitative PCR and Solexa order-checking to the research of MICRORNA-373; And these methods are used for the scientific research aspect more; The incompatibility clinical application; And detect RNA than genetic analysis more science (the DNA analysis major part is on the presentation of susceptibility; RNA is functional embodiment), than analysis of protein more reliable (mRNA and albumen are transcribed sometimes asynchronous).Detection technique and test kit according to existing literature data MicroRNA-373 level do not appear in the newspapers.
The inventor is in the requirement to the novelty invention; Designed (cancer patients, high risk population, normal control) different pieces of information example group; Detect with hybridization in situ technique; The result shows above cancer disease patient MICRORNA-373 high expression level, and the high risk population has and expresses 15-25% in various degree, and normal control all is low the expression.Show that the various cancers of MICRORNA-373 become the important symbol thing of examination in early stage.
Hybridization in situ technique (in situ hybridization) combines molecular biology and cytochemistry technology, is probe with the nucleic acid molecule of mark, in the technology of histocyte in situ detection specific nucleic acid molecule.Its principle is to make the nucleic acid strand (being probe) that contains distinguished sequence, process mark; Under optimum conditions with histocyte in the complementary nucleic acid strand be that target nucleic acid is hybridized; With radioautograph or immunocytochemistry label probe is surveyed again, thereby shown special DNA or RNA molecule at cell in-situ.
The probe of in situ hybridization is molecule or sequence the unknown but the known nucleic acid molecule of molecule (though indeterminate this molecule full sequence of known array; But what target molecule known its is directed against), the kind of probe can be divided into dna probe, cDNA probe, cRNA probe and synthetic oligonucleotide probe again by the properties of nucleic acids difference.For the ease of spike, probe must be used certain means mark in addition, is beneficial to later detection.Affinity tag commonly used comprises radionuclide and non-radioactive marker's two big classes.Isotopic label commonly used has
3H,
35S,
125I with
32P.Advantages such as susceptibility is high though isotopic label has, the back of the body end is comparatively clear because ri all can damage human and environment, have by the substituted trend of heterotope recently.At present the most frequently used in the heterotope affinity tag have three kinds of vitamin H, digoxin and resorcinolphthaleins.The method that detects these affinity tags all is a sensitive extremely.
According to used probe and to detect nucleic acid difference can be divided into DNA-DNA again, RNA-DNA, RNA-RNA hybridization.No matter but the hybridization of any form, all must be through five big processes, promptly histiocytic fixing, prehybridization, hybridization, flushing and demonstration.The present invention adopts the hybridization mode of RNA-RNA; Synthetic probe (RNA) and the target RNA that detects are the principles that adopts base complementrity (hybridization is complementary); Pass through the contrast of long-time research and observation and miRNA chip of expression spectrum simultaneously, start and termination place the result not influence of residue to detecting.
In view of the diagnosis of cancer clinically (medical imaging and biochemical indicator thing all are the diagnosis after tumour forms) at present is the diagnosis in late period, treatment also is a treatment of late stage, the treatment pattern that causes mortality ratio not fallen.Original intention of the present invention is to want to change at present the diagnosis and treatment pattern of major disease clinically; Become preventative preventiveing treatment of disease from treating the disease affected; Reach preventative diagnosis and treatment; Present medical imaging means and numerous biochemical marker can't be detected become rna level before the cancer and quantize changes technology, do the technological breakthrough of novelty, provide that to become the rna level examination before the cancer technological.Making has had a preceding technology that becomes the real early screening of rna level of new cancer clinically, for the diagnosis and treatment of clinical cancer are raced against time and the space.
Summary of the invention
The object of the invention at first provides a kind of hybridization in situ detection kit, and it comprises in situ hybridization detection probes and affinity tag.
Secondly, the present invention also will provide the mentioned reagent box to be used for becoming (particularly esophagus cancer) examination in early stage and art recurrence, shifting the relevant in situ hybridization detection method of early warning with various cancers.
For realizing the object of the invention; Technical scheme of the present invention is following: the present invention at first provides a kind of hybridization in situ detection kit, and it comprises hybridization probe and affinity tag, wherein; Described hybridization probe sequence is the complementary sequence of sequence shown in the sequence table SEQ ID NO.1; Sequence number: NR_029866, MICRORNA-373 consecutive nucleotides sequence length is 69bp, is positioned at karyomit(e) 19q13.42 " on.
A preferred version of test kit of the present invention is that described affinity tag is selected from radioactive substance, chemoluminescence or substance that show color, vitamin H, metal king crab, resorcinolphthalein, enzyme and nano material.
A preferred version of test kit of the present invention is also to comprise hybridization solution.
A preferred version of test kit of the present invention is also to comprise toughener.
A preferred version of test kit of the present invention is also to comprise developer.
Canceration of the present invention MICRORNA-373 kit for screening in early stage using value is, to various cancerations (esophagus cancer) examinations in early stage, and after the canceration or postoperative recurrence, transfer, diffusion generation early warning, further cooperates clinical treatment.
The present invention also provides a kind of detection method of MICRORNA-373 in situ hybridization, may further comprise the steps:
(1) described in the above hybridization probe and target sequence can form under the condition of stablizing hybridization complex, and RNA to be measured in the substrate is contacted with hybridization probe, form hybridization complex; With
(2) detect said hybridization complex.
Detection method of the present invention, wherein preferably, the described condition of stablizing hybridization complex that forms is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour.
Detection method of the present invention, wherein preferably, described substrate is selected people's blood leucocyte sample or other organ-tissue cell specimen for use.More preferably be that described blood preparation or other organ-tissue cell specimen are from various cancers (particularly esophagus cancer) patient, various cancer high risk population, healthy normal population.
Detection method of the present invention, wherein preferably, described cancer high risk population, cancer build up a family fortune well family, various cancer patients (particularly esophagus cancer).
Detection kit of the present invention is to adopt nucleic acid hybridization technique and groupization immunization method to combine; With MICRORNA-373 is detected object; Synthesising probing needle is the complementary sequence of MICRORNA-373 sequence, and the substrate of detection is the expression amount of blood of human body sample white corpuscle or histiocytic RNA.The display packing of hybridization in situ technique can provide sxemiquantitative or the quantitative expression deciding degree of MICRORNA-373.The expression amount of above RNA is judged in colour developing according to hybridization back immunohistochemical methods, and normal people MICRORNA-373 is low to express, i.e. colour developing on a small quantity, and MICRORNA-373 has apparent difference at various cancer patients and normal control, and this expression of gene amount is all higher than normal people expression amount.
The component of diagnostic kit of the present invention is by hybridization probe, hybridization solution, developer, compositions such as synergistic agent.The nucleic acid hybridization principle of this test kit is that the molecular biology insider all knows, and the concrete operations step is to carry out quantitative analysis, result's report under sample disposal, prehybridization, hybridization, immunohistochemical staining, the mirror, and wherein the concrete steps of hybridization comprise:
1). sample to be measured is put into reactive tank;
2). instrument discards liquid automatically, adds Digestive system automatically;
3). instrument discards liquid automatically, and the back is fixing automatically;
4). instrument discards liquid automatically, automatically prehybridization (42 ℃);
5). instrument discards liquid automatically, cleans automatically;
6). instrument discards liquid automatically, automatically hybridization (42 ℃);
7). instrument discards liquid automatically, cleans automatically;
8). instrument discards liquid automatically, and automatic and DIG antibody is cultivated (room temperature);
9). instrument discards liquid automatically, cleans colour developing automatically;
10). take out the mounting microscopy.
The scheme of a preferred embodiment of the present invention is: with MICRORNA-373 synthetic nucleic probe with digoxigenin labeled (cDNA of digoxigenin labeled, RNA and oligonucleotide probe; Not only probe has a biotin labeling advantage; Also having overcome biotin labeled probe is organized the endogenous vitamin H to do shortcomings such as sorrow in the crossover process in position); This hybridization probe and the leukocytic RNA nucleic acid to be measured of blood of human body are hybridized,, under light microscopic, observe existence and the location of RNA again with the method colour developing of immunohistochemical methods; According to painted cell count, judge the expression amount of purpose RNA.
The inventive method is a nucleic acid hybridization in situ technology commonly used at present; This method is through detecting the MICRORNA-373 expression amount in the substrate cell; Be used for confirming that various cancer pathology develop the RNA variable quantity in early stage (particularly esophagus cancer), the various cancerations of early warning (esophagus cancer) whether take place and various cancer patients treatment after the prediction of whether recurring, shifting.Because MICRORNA-373 is low the expression in the normal people, if the MICRORNA-373 expression amount increases, the risk of suffering from cancer be described, explain that canceration takes place, or the cancer patient postoperative recurs, shifts, thus the diagnostic message of acquisition cancer.A test kit can many person-portions use or person-portion use.
The present invention has following beneficial effect: clinical meaning of the present invention is the more early stage variation that detects MICRORNA-373 expression amount in various cancerations (special esophagus cancer) generation and the pathology evolution process of following the tracks of, and the various cancers of early warning take place, development trend.Diagnostic kit of the present invention and other detection and cancer markers clinically, and the medical imaging inspection has apparent difference.The present invention can detect the MICRORNA-373 unconventionality expression at rna level; Before the recurrence of occupancy carninomatosis kitchen range is not found in the medical imaging inspection; Before the cancer biochemical indicator does not produce unusually; Also do not form before the tumour, can accomplish the information acquisition of above abnormal gene expression early, predict for real early warning of clinical carninomatosis patient and treatment back transfer and relapse early.So just might implement early screening, early prevention, the early treatment of cancer, might from the source, thoroughly effect a radical cure various cancer foul diseases.
In addition, characteristics highly sensitive, high specificity that test kit provided by the invention has, simultaneously, detection method of the present invention is convenient and simple for operation, can be widely used and promoted in Municipal Hospitals.
Description of drawings
Fig. 1 is a MICRORNA-373 hybridization in situ technique schema of the present invention.
Fig. 2 is that esophagus cancer patient MICRORNA-373 expresses picture in the embodiment of the invention.
Fig. 3 is high risk population's picture in the embodiment of the invention.
Fig. 4 is that normal people MICRORNA-373 expresses picture in the embodiment of the invention.
Embodiment
Below in conjunction with embodiment, content of the present invention is described more specifically.Should be appreciated that following embodiment is used for explanation and non-limiting content of the present invention, any pro forma change or accommodation will fall into protection scope of the present invention.
Prepare the in situ hybridization test kit of present embodiment according to ordinary method, this test kit comprises that wherein: the probe mark thing of present embodiment is selected digoxin for use with hybridization probe, affinity tag, the specification sheets of MICRORNA-373 design.
The test kit hybridization solution is formed:
| Digestive system | 100 μ L/ |
1 pipe/box | Colourless transparent liquid |
| Protection liquid | 100 μ L/ |
1 pipe/box | Colourless transparent liquid |
| Prehybridization solution | 1300 μ L/ pipe | 2 pipe/boxes | Colourless transparent liquid |
| The justice hybridization solution | 10 μ L/ |
1 pipe/box | Colourless transparent liquid |
| The antisense hybridization solution | 10 μ L/ |
1 pipe/box | Colourless transparent liquid |
| Confining liquid | 1000 μ L/ |
1 pipe/box | Colourless transparent liquid |
| The alkaline |
1 μ L/ |
1 pipe/box | Colourless transparent liquid |
| Developer A | 175 μ L/ |
1 pipe/box | Yellow liquid |
| Developer B | 320 μ L/ |
1 pipe/box | Colourless transparent liquid |
| The damping fluid I | The 90mL/ |
1 bottle/box | Light yellow or colourless transparent liquid |
| The damping fluid II | The 80mL/ |
1 bottle/box | Light yellow or colourless transparent liquid |
| The damping fluid III | The 20mL/ bottle | 3 bottle/boxes | Light yellow or colourless transparent liquid |
| The damping fluid IV | The 90mL/ |
1 bottle/box | Light yellow or colourless transparent liquid |
| Stationary liquid | The 90mL/ |
1 bottle/box | Colourless transparent liquid |
| The positive control sample | 6/box | ? | ? |
The reagent preparation working concentration
1). 10 * damping fluid I is diluted to 1 * damping fluid I with tri-distilled water by 1:10;
2). 20 * damping fluid II is diluted to 2 * damping fluid II with tri-distilled water by 1:10;
Be diluted to 0.2 * damping fluid II by 1:100; Be diluted to 0.1 * damping fluid II by 1:200;
3). 10 * damping fluid III is diluted to 1 * damping fluid III with tri-distilled water by 1:10;
4) .10 * damping fluid IV with tri-distilled water by 1:10 be diluted to * the damping fluid IV (get 1#, 2#, each 10mL of 3#, add water to 100mL both can).
Embodiment 2
Use the implementation process of nucleic acid hybridization in situ detection method to each group blood preparation MICRORNA-373 expression amount:
1). get two of samples to be measured;
2). in glass jar, add Digestive system (Digestive system 100 μ L add 1 * damping fluid I 99.9ml, are working concentration) 50 ml, 37 ℃ of water-bath preheating 10min put 16 slides into, handle 12 min, use 1 * damping fluid I to wash 5min again for 37 ℃;
3). (protection liquid 1ml adds 1 * damping fluid
to the protection liquid with 0.2%; 99ml is working concentration) wash 10min; Tri-distilled water is washed 5min (above process is all carried out at glass jar); Take out slide, let its seasoning;
4). slide is put into the box of preserving moisture, add prehybridization solution 25 μ L/ sheets (being added in the place of cell), covered, the lid box of tightly preserving moisture is placed in 42 ℃ of constant water bath box more than the 3h;
5). take out slide, discard deckglass, slide is put into glass jar, the ethanol with 70%, 90%, 95% is respectively washed 2min, takes out seasoning;
6). slide is put into the box of preserving moisture, and one adds just hybridization solution 25 μ L/ sheets, and another adds antisense hybridization solution 25 μ L/ sheets, and covered is covered the box of tightly preserving moisture, and is placed on 16-24h in 42 ℃ of constant water bath box;
7). take out slide, discard deckglass, slide is put into glass jar:
In 42 ℃ of constant water bath box, wash twice, each 15min with 2 * damping fluid II;
In 42 ℃ of constant water bath box, wash once each 15min with 0.2 * damping fluid II;
In 42 ℃ of constant water bath box, wash twice, each 15min with 0.1 * damping fluid II;
8). wash 30s with 1 * damping fluid III, take out slide, seasoning;
9). slide is put into the box of preserving moisture, add 0.5% confining liquid (the 1ml confining liquid adds 5ml 1 * damping fluid III), 100 μ L/ sheets, cover the box of tightly preserving moisture, at room temperature act on 30min.(this step need not add deckglass);
10). take out slide, wash 30s with 1 * damping fluid III, seasoning;
11). slide is put into the box of preserving moisture; Add X-AP antibody (getting a pipe alkaline phosphatase enzyme antibody) 100 μ L/ sheets, cover the box of tightly preserving moisture and at room temperature act on 30min to wherein adding 1.8ml 1 * damping fluid III; Time can not be long, otherwise can produce false positive (this step need not add deckglass);
12). take out slide, wash 3 times, each 15min with 1 * damping fluid III;
13). wash 2min with 1 * damping fluid IV, add developer (developer A73.3 μ L, developer B157.5 μ L is added in 30mL 1 * damping fluid IV, mixing), room temperature lucifuge 16h is to more than the 18h;
14). wash 5min with tri-distilled water, seasoning, (add with glycerine 10% 1 * damping fluid I mixing) mounting microscopy.
Nucleic acid hybridization in situ detection method of the present invention is used digoxigenin labeled with goal gene; Become the RNA nucleic probe; The RNA nucleic acid to be measured of probe and human leukocytes is hybridized,, therefore under light microscopic, observe existence and the location of RNA again with the method colour developing of immunohistochemical methods; According to painted cell count, judge the expression amount of purpose RNA.
Esophagus cancer patient's 20 examples, high risk population's (esophagus cancer family members' history) 20 examples, normal control group 20 examples.Take out all people's to be checked peripheral blood 3-5 milliliter (separation white corpuscle) and do in situ hybridization.The result representes that all cancer patients MICRORNA-373 expression amounts are high, and cell dyeing is dark; The high risk population expresses slightly and reduces, decimal dyeing; Normal control group MICRORNA-373 expression amount is low, the dyeing of cell minority, and concrete outcome is seen Fig. 2, Fig. 3, Fig. 4.
| Esophagus cancer cancer number | Expression amount % | High-risk number | Expression amount % | Normal number | |
| 1 | 82 | 1 | 23 | 1 | 2 |
| 2 | ? 80 | 2 | 22 | 2 | 0 |
| 3 | ? 78 | 3 | 20 | 3 | 0 |
| 4 | ? 68 | 4 | 16 | 4 | 2 |
| 5 | ? 64 | 5 | 22 | 5 | 0 |
| 6 | ? 66 | 6 | 18 | 6 | 0 |
| 7 | ? 76 | 7 | 16 | 7 | 0 |
| 8 | ? 82 | 8 | 22 | 8 | 3 |
| 9 | ?70 | 9 | 14 | 9 | 0 |
| ? 10 | ?76 | ? 10 | 17 | ? 10 | 0 |
| ? 11 | ?80 | ? 11 | 20 | ? 11 | 3 |
| ? 12 | ?76 | ? 12 | 28 | ? 12 | 0 |
| ? 13 | ? 87 | ? 13 | 19 | ? 13 | 0 |
| ? 14 | ? 78 | ? 14 | 23 | ? 14 | 0 |
| ? 15 | ? 73 | ? 15 | 22 | ? 15 | 0 |
| ? 16 | ?76 | ? 16 | 22 | ? 16 | 2 |
| ? 17 | ?74 | ? 17 | 27 | ? 17 | 0 |
| ? 18 | ?68 | ? 18 | 16 | ? 18 | 0 |
| ? 19 | ? 86 | ? 19 | 24 | ? 19 | 0 |
| 20 | 78 | 20 | ? 20 | 20 | 2 |
。
Claims (10)
1. a hybridization in situ detection kit comprises hybridization probe and affinity tag, it is characterized in that, described hybridization probe is the complementary sequence of sequence shown in the sequence table SEQ ID NO.1.
2. test kit as claimed in claim 1 is characterized in that, described affinity tag is selected from radioactive substance, chemoluminescence or substance that show color, vitamin H, metal king crab, resorcinolphthalein, enzyme and nano material.
3. test kit as claimed in claim 1 is characterized in that this test kit also comprises hybridization solution.
4. test kit as claimed in claim 1 is characterized in that this test kit also comprises synergistic agent.
5. test kit as claimed in claim 1 is characterized in that this test kit also comprises developer.
6. microRNA-373 gene hybridization in situ detection method is characterized in that this method may further comprise the steps:
(1) can form under the condition of stablizing hybridization complex at described hybridization probe of claim 1 and target sequence, RNA to be measured in the substrate is contacted with hybridization probe, form hybridization complex; With
(2) detect said hybridization complex.
7. detection method as claimed in claim 6 is characterized in that, the described condition of stablizing hybridization complex that forms is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour.
8. detection method as claimed in claim 6 is characterized in that, described substrate is selected people's blood leucocyte sample for use.
9. detection method as claimed in claim 8 is characterized in that, described blood leucocyte sample is selected from cancer, high risk population, normal people's sample.
10. detection method as claimed in claim 9 is characterized in that, said sample comprises high risk population's precancerosis reason evolution process of various cancers clinically, and recurrence and the transfer pathology evolution process of various cancer after treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104196205A CN102533978A (en) | 2011-12-15 | 2011-12-15 | Kit and method for detecting horizontal in situ hybridization of MICRORNA-373 at the early pathological evolution stage of a variety of cancers and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104196205A CN102533978A (en) | 2011-12-15 | 2011-12-15 | Kit and method for detecting horizontal in situ hybridization of MICRORNA-373 at the early pathological evolution stage of a variety of cancers and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102533978A true CN102533978A (en) | 2012-07-04 |
Family
ID=46342001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104196205A Pending CN102533978A (en) | 2011-12-15 | 2011-12-15 | Kit and method for detecting horizontal in situ hybridization of MICRORNA-373 at the early pathological evolution stage of a variety of cancers and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102533978A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101389770A (en) * | 2006-01-05 | 2009-03-18 | 俄亥俄州立大学研究基金会 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of solid cancers |
| WO2009036332A1 (en) * | 2007-09-14 | 2009-03-19 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
-
2011
- 2011-12-15 CN CN2011104196205A patent/CN102533978A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101389770A (en) * | 2006-01-05 | 2009-03-18 | 俄亥俄州立大学研究基金会 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of solid cancers |
| WO2009036332A1 (en) * | 2007-09-14 | 2009-03-19 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
Non-Patent Citations (3)
| Title |
|---|
| KUEN-HAUR LEE ET AL.: "MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer", 《EXPERIMENTAL CELL RESEARCH》, vol. 315, no. 15, 10 September 2009 (2009-09-10), pages 2529 - 2538 * |
| LEE,K.H. ET AL.: "NR_029866", 《GENBANK》, 29 October 2009 (2009-10-29), pages 1 - 2 * |
| P. MATHIJS VOORHOEVE ET AL.: "A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors", 《CELL》, vol. 124, no. 6, 24 March 2006 (2006-03-24), pages 1169 - 1181 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102559881A (en) | Messenger ribonucleic acid (mRNA) level in-situ hybridization detection kit for neoplasia early stage of intracranial glioma, and detection method and application | |
| CN102586419A (en) | MRNA level in-situ hybridization detection kit for beta-catenin of liver cancer prophase as well as detection method and application of mRNA level in-situ hybridization detection kit | |
| CN102559887A (en) | Messenger ribonucleic acid (mRNA) level in-situ hybridization detection kit for JAGGED1 in early stage of pathological change of breast cancer bone metastasis, and detection method and application | |
| CN102533976A (en) | Kit and method for detecting horizontal in situ hybridization of MICRORNA-21 at the early pathological evolution stage of a variety of cancers and application thereof | |
| CN102559884A (en) | LET-7micro ribose nucleic acid (MIRNA) level in-situ hybridization detection kit for pathologic evolution early stage of various cancer, and detection method and application | |
| CN102443641A (en) | Various early-stage cancer pathology evolution MICRORNA-16 level in situ hybridization detection kit, detection method thereof and application thereof | |
| CN102443647A (en) | In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-145 level at pathologic evolution early stages of various colon cancers as well as microRNA-145 in-situ hybridization detection method and application of microRNA-145 to preparation of in-situ hybridization detection kit for colon cancers | |
| CN102443643A (en) | Kit for assaying MICRORNA-34 level in early stage of pathologic evolution of various cancers through in situ hybridization and assay method and application | |
| CN102605056A (en) | In-situ hybridization assay kit for mRNA level of premalignant pancreatic cancer ATDC (telangiectasia group D associated protein) gene as well as assay method and application | |
| CN102443642A (en) | In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-92A level at pathologic evolution early stage of colon cancer as well as microRNA-92A in-situ hybridization detection method and application of microRNA-92a to preparation of in-situ hybridization detection kit for colon cancer | |
| CN102443644A (en) | In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-29A level at pathologic evolution early stage of colon cancer as well as microRNA-29A in-situ hybridization detection method and application of microRNA-29a to preparation of in-situ hybridization detection kit for colon cancer | |
| CN102628078A (en) | MicroRNA-155 level in various types of cancerous lesions prophase in situ hybridization detection kit, detection method and application thereof | |
| CN102533978A (en) | Kit and method for detecting horizontal in situ hybridization of MICRORNA-373 at the early pathological evolution stage of a variety of cancers and application thereof | |
| CN102605060A (en) | In-situ hybridization assay kit for premalignant lung cancer 14-3-3thta level as well as assay method and application | |
| CN102533977A (en) | Kit and method for detecting horizontal in situ hybridization of MICRORNA-372 at the early pathological evolution stage of a variety of cancers and application thereof | |
| CN102533979A (en) | Kit and method for detecting horizontal in situ hybridization of MICRORNA-520 at the early pathological evolution stage of a variety of cancers and application thereof | |
| CN104131064A (en) | In-situ hybridization detection kit of miR-378 in early stage of pathologic evolution of gastric cancer, detection method and application | |
| CN102533990A (en) | In situ hybridization detection kit for mRNA level at precancerous stage of breast cancer, detection method and application thereof | |
| CN102533983A (en) | Horizontal in-situ hybridization detection kit and detection method as well as application for MICRORNA-330 in earlier stage of cancer pathologic evolution | |
| CN102443650A (en) | In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-233 level at pathologic evolution early stage of colon cancer as well as microRNA-233 in-situ hybridization detection method and application of microRNA-233 to preparation of in-situ hybridization detection kit for colon cancer | |
| CN102443646A (en) | In situ hybridization detection kit for MICRORNA-223 level of early-stage lung cancer pathology evolution, detection method thereof and application thereof | |
| CN102443645A (en) | In-situ hybridization detection kit and detection method for MICRORNA (MICRO Ribonucleic Acid)-25 level at pathologic evolution early stage of colon cancer as well as application of microRNA-25 to preparation of in-situ hybridization detection kit for colon cancer | |
| CN102559876A (en) | Level in situ hybridization detection kit for detecting MICRORNA-16-1 in earlier period of pathological changes of cancers as well as detection method and application | |
| CN102443648A (en) | In-situ hybridization detection kit for microRNA-182 level in early stage of pathological evolution of various cancers, and detection method and application thereof | |
| CN102533986A (en) | MicroRNA-15a-level in-situ hybridization detection kit for prophase of cancer pathologic evolution, detection method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120704 |